Pfizer updated CHANTIX label to quit smoking with more warnings
Pfizer’s CHANTIX label in the U.S. to include a warning for neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior. – Cigarette smoking is associated with significant morbidity and mortality. Smoking is the leading preventable cause of disease and premature death in the United States, with more than 438,000 U.S. deaths annually attributable to smoking. Patients who smoke cigarettes should be counseled to quit. CHANTIX was approved in May of 2006 in the U.S. as an aid to smoking cessation.